Business News

    Microba Life Sciences (ASX:MAP) acquires UK's Invivo Clinical for global growth

    Article Image

    Microba Life Sciences acquired Invivo Clinical, a microbiome testing company in the UK.

    The move aligns with Microba's international testing services growth strategy, focusing on the key UK healthcare market.

    The acquisition, which secured 100% of Invivo's issued share capital, grants Microba a dominant position, expanded customer base, and broader geographical reach in the UK healthcare landscape.

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa